In addition, our findings also revealed that selegiline, a MAOB pharmacal inhibitor, exerted an anti-atherosclerotic effect not only through its protective effect against endothelial dysfunction, but also partly by modulating the composition and function of the gut microbiome, which provided evidence for selegiline as a potential drug for treating ACVDs. The gene discussed is MAOB; the disease is endothelial dysfunction.